- Titel
- SARS-CoV-2 in pediatric cancer
- Untertitel
- a systematic review
- Zitierfähige Url:
- https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-908999
- Quellenangabe
- European journal of pediatrics
Erscheinungsjahr: 2022
Jahrgang: 181
Seiten: 1413-1427
E-ISSN: 1432-1076 - Erstveröffentlichung
- 2022
- Abstract (EN)
- The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 in Wuhan challenges pediatric oncologists in an unexpected way. We provide a comprehensive overview, which systematically summarizes and grades evidence (QoE) on SARS-CoV-2 infections in pediatric cancer patients at 1.5 years of pandemic. A systematic literature search in PubMed combined with an additional exploratory literature review in other international databases was conducted to identify studies on children (aged < 18 years) with a malignant disease and COVID-19 infections. In total, 45 reports on 1003 pediatric cancer patients with SARS-CoV-2 infections were identified out of 1397 reports analyzed. The clinical course of COVID-19 was reported mild or moderate in 358 patients (41.7%), whereas 11.1% of patients showed severe COVID-19. In 12.7% of patients, chemotherapy was postponed, whereas 19% of patients with different underlying malignancies received chemotherapy during SARS-CoV-2 infection. Twenty-five patients with SARS-CoV-2 infections died, potentially related to COVID-19. Conclusion: Despite a favorable COVID-19 outcome in most pediatric cancer patients, the morbidity is reported higher than in children without comorbidities. However, no severe COVID-19 complications were associated to the continuation of chemotherapy in some cohort studies and reports on two patients. Therefore, the risk of cancer progress or relapse due to interruption of chemotherapy has carefully to be weighed against the risk of severe COVID-19 disease with potentially fatal outcome.
- Andere Ausgabe
- Link zum Artikel der zuerst in der Zeitschrift „European journal of pediatrics” bei Springer Link erschienen ist.
DOI: 10.1007/s00431-021-04338-y - Verweis
- Ergänzendes Material ist unter folgendem Link zu finden.
Link: https://link.springer.com/article/10.1007/s00431-021-04338-y#Sec18 - Freie Schlagwörter (DE)
- Pädiatrie, Krebs, Malignität, Chemotherapie, SARS-CoV-2, COVID-19
- Freie Schlagwörter (EN)
- Pediatric, Cancer, Malignancy, Chemotherapy, SARS-CoV-2, COVID-19
- Klassifikation (DDC)
- 610
- Verlag
- Springer Science + Business Media B.V., Dordrecht [u.a.]
- Version / Begutachtungsstatus
- publizierte Version / Verlagsversion
- URN Qucosa
- urn:nbn:de:bsz:14-qucosa2-908999
- Veröffentlichungsdatum Qucosa
- 04.06.2024
- Dokumenttyp
- Artikel
- Sprache des Dokumentes
- Englisch
- Lizenz / Rechtehinweis
CC BY 4.0